Feed it a chromosome-scale genome — no phenotype data, no QTL mapping, no field trials — and it returns editable, mechanistically ranked disease-resistance targets.
The Interrogation Protocol
The current approach is slow, phenotype-reliant, and structurally incapable of matching the pace at which pathogens evolve. Multi-year breeding cycles chase traits that disease pressure has already moved past.
The result is a massive, under-tooled protein production system — one where the genetics layer has barely been touched by computation, even as disease losses climb and global demand accelerates.
Can't discover what you can't observe. Breeding programs require years of field data before selection even begins.
Selective breeding operates on generational timescales. Pathogens evolve orders of magnitude faster.
Traditional approaches surface correlations, not causes. You get markers, not targets.
The commercial demand for resilience is immediate. And the industry is already primed for genetic solutions — making this the optimal wedge market before scaling across species.
Mass mortality events routinely wipe out 50–90% of production. The economic toll is existential for growers and the genetic bottleneck is only tightening.
Genetic improvement is already a proven lever in oyster aquaculture. Growers pay premiums for resilient seed. The demand signal is established — the technology to serve it hasn't been.
What works in oysters transfers. The computational workflow, the target library, the validation framework — all of it is designed to port to shrimp, salmon, tilapia, and beyond.
OG is a computation-first biology company. Our enterprise value compounds in the discovery engine, the accumulating target library, the validation datasets, and a workflow that transfers across species.
How it scales
Deep tech meets food security
Aquaculture is the fastest-growing protein sector on Earth and its genetics layer is untouched. We're bringing the computational rigor that transformed row-crop agriculture into the last major food system that hasn't had it.